title: The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study.
abstract: The antiemetic efficacy of metoclopramide and lorazepam (MTC + L) versus alizapride and lorazepam (ALZ + L) was compared in 100 patients receiving chemotherapy, in a prospective randomized double-blind study. In highly emetogenic (HE) regimen (including platinum) patients received MTC 1 mg/kg or ALZ 3 mg/kg x 4 doses, and lorazepam 2.5 mg 30 min before therapy. In moderately emetogenic (ME) regimen patients received MTC 0.5 mg/kg or ALZ 1.5 mg kg x 3 doses, and lorazepam 2.5 mg 30 min before therapy. In both HE and ME regimen groups there was no statistically significant difference between MTC + L and ALZ + L treatments as regards the number of vomiting episodes, the duration of emesis and nausea, the intensity of nausea and side effects, but a statistically significant difference between treatments was found in the HE group where MTC-L was superior to ALZ + L in obtaining complete protection from vomiting (37 vs 11%, p = 0.05). No significant difference in side effects was observed.
authors.affiliation: Cattedra di Oncologia Medica, Università di Verona, Italia.
authors.forename: A
authors.initials: A
authors.lastname: Molino
authors.forename: L
authors.initials: L
authors.lastname: Guglielmo
authors.forename: M E
authors.initials: ME
authors.lastname: Azzolini
authors.forename: P
authors.initials: P
authors.lastname: Biondani
authors.forename: M C
authors.initials: MC
authors.lastname: Capelli
authors.forename: A
authors.initials: A
authors.lastname: Grandinetti
authors.forename: C
authors.initials: C
authors.lastname: Griso
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: N
authors.initials: N
authors.lastname: Martini
authors.forename: R
authors.initials: R
authors.lastname: Zanotti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000627:therapeutic use; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D011759:Pyrrolidines; D008787:Metoclopramide; D008140:Lorazepam; C033968:alizapride